Esperion Therapeutics, Inc. (ESPR) SEC Filing 8-K Material Event for the period ending Wednesday, June 26, 2019

Esperion Therapeutics, Inc.

CIK: 909037 Ticker: ESPR

View differences made from one to another to evaluate Esperion Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Esperion Therapeutics, Inc..


Assess how Esperion Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Esperion Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Esperion Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ESPR
CIK: 1434868
Form Type: 8-K Corporate News
Accession Number: 0001104659-19-037687
Submitted to the SEC: Wed Jun 26 2019 5:18:23 PM EST
Accepted by the SEC: Wed Jun 26 2019
Period: Wednesday, June 26, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: